Antiepileptic drugs and borderline personality disorder

Antiepileptic Drugs to Treat Psychiatric Disorders

Volumn , Issue , 2008, Pages 343-348

  Zanarini, Mary C ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924651245     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849382666-21     Document Type: Chapter

References (32)

1. Bender DS, Dolan RT, Skodol AE, et al. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001; 158(2):295-302.
2. Zanarini MC, Frankenburg FR, Khera GS, et al. Treatment histories of borderline inpatients. Compr Psychiatry 2001; 42(2):144-150.
3. Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization of borderline patients and axis II comparison subjects followed prospectively for six years. J Clin Psychiatry 2004; 65(1):28-36.
4. Akiskal HS, Chen SE, Davis GC, et al. Borderline: an adjective in search of a noun. J Clin Psychiatry 1985; 46(2):41-48.
5. Gunderson JG, Weinberg I, Daversa MT, et al. Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry 2006; 163(7):1173-1178.
6. Zanarini MC, Frankenburg FR, Hennen J, et al. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004; 161(11):2108-2114.
7. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143(4):519-522.
8. De la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4(4):479-486.
9. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56(11):506-510.
10. Coccaro EF, Harvey PH, Kupshaw-Lawrence E, et al. Development of neuropharmacologically based assessments of impulsive aggressive behavior. J Neuropsychiatry 1991; 3(suppl):44-51.
11. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scalepreliminary report. Psychopharmacol Bull 1973; 9(1):13-28.
12. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7(1):33-37.
13. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10:799-812.
14. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62(3): 199-203.
15. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162(3):621-624.
16. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63(5):442-446.
17. Zanarini MC, Gunderson JG, Frankenburg FR, et al. The revised diagnostic interview for borderlines: discriminating BPD from other axis II disorders. J Personal Disord 1989; 3(1): 10-18.
18. Simeon D, Baker B, Chaplin W, et al. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr 2007; 12(6):439-443.
19. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51(3): 333-343.
20. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psycho-pharmacol 2005; 19(3):287-291.
21. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65(11):1515-1519.
22. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57(5): 495-499.
23. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006; 26(1):61-66.
24. Bullinger M, Kirchberger I. SF-36 Health Survey. Goettingen, Germany: Hogrefe, 1998.
25. Horowitz LM, Rosenberg SE, Baer BA, et al. Inventory of interpersonal problems: psychometric properties and clinical applications. J Consult Clin Psychol 1988; 56(6):885-892.
26. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66(9):1111-1115.
27. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991; 148(12):1647-1658.
28. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004; 6(1):55-70.
29. Linehan MM, Armstrong HE, Suarez A, et al. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991; 48(12):1060-1064.
30. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 1999; 156(10): 1563-1569.
31. Giesen-Bloo J, van Dyck R, Spinhoven P, et al. Outpatient psychotherapy for borderline personality disorder. Arch Gen Psychiatry 2006; 63(6):649-658.
32. Clarkin JF, Levy KN, Lenzenweger MF, et al. Evaluating three treatments for borderline personality: a multiwave study. Am J Psychiatry 2007; 164(6):922-928.